Methadone or Enhanced Buprenorphine to Address Retention Among Patients not Optimally Benefitting from Office-based Buprenorphine – a Hybrid Effectiveness/Implementation Trial

Details coming soon...

CTN Protocol ID: 
CTN-0131
Status: 
Development

Principal Investigator(s)

David Fiellin, M.D.

Professor of Medicine and Public Health
Yale University School of Medicine

333 Cedar Street
P.O. Box 208056
New Haven, CT 06520
United States